Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVIDIA

SPDR Gold Trust

Plug Power

Novavax, Nvidia, Plug Power and gold were our top stock trades for Monday. Let's get a look at the stock charts after a week of record highs.

4 Top Stock Trades for Monday: NVAX, NVDA, PLUG, Gold

Novavax is long on promises and it's time to deliver more concrete milestones. Meanwhile, NVAX stock remains a wild trading vehicle.

Novavax Stock Has Too Dedicated a Fanbase to Bet Against

Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.

Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down

After seeing gains early in the week, here's why investors in vaccine maker Novavax is seeing declines of more than 20% today in NVAX stock. The post NVAX Stock: The Covid-19 Vaccine News Sending Novavax Plunging appeared first on InvestorPlace.

NVAX Stock: The Covid-19 Vaccine News Sending Novavax Plunging

NVAX stock could drop on further disappointment. But it's poised to rally big if its Covid-19 vaccine beats expectations.

Despite Novavax's Challenges, NVAX Stock Could Still Pop

Biotechnology concern Novavax, Inc. ( NASDAQ:NVAX) is plummeting today, last seen down 18.6% to trade at $192.20, after the drug maker said it would not seek emergency use authorization from the U.S. Federal Drug Administration (FDA) for its coronavirus vaccine until the fourth quarter, delaying the process one more time as it struggles to access raw materials and equipment.

Novavax Stock Plummets After Covid-19 Vaccine Update

BioNTech SE

Dynavax Technologies

Moderna

Each vaccine stock had its own separate catalyst.

Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week

The stock price of Novavax, Inc. (NASDAQ: NVAX) fell over 11% pre-market. This is why it happened.

NVAX Stock Price Falls Over 11% Pre-Market: Why It Happened

Novavax, Inc (NASDAQ: NVAX) shares slipped nearly 10% in the after-hours trading on Thursday. What's Moving?

Here's Why Novavax Stock Is Crashing

Novavax's (NVAX) CEO Stan Erck on Q2 2021 Results - Earnings Call Transcript

Novavax Inc. shares fell in the extended session Thursday after the biotech's wider-than-expected loss on the quarter overshadowed positive results for its COVID-19 vaccine booster.

Earnings Results: Novavax stock drops as wider-than-expected loss overshadows vaccine booster data

Novavax announced that it will delay submission of its Covid-19 vaccine to the Food and Drug Administration for emergency use authorization until its fourth quarter.

Novavax delays Covid vaccine emergency authorization submission to FDA until fourth quarter

Shares of Novavax (NASDAQ:NVAX) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 1483.33% year over year to ($4.75), which missed the estimate of ($3.63).

Recap: Novavax Q2 Earnings

GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2021.

Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series Analysis of sera from primary vaccination series also showed cross-reactive functional antibodies to Alpha, Beta and Delta variants, all of which increased 6- to 10-fold with boost Study reinforces mostly mild and transient side effect profile GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant, NVX-CoV2373, given six months after an initial two-dose regimen, elicited a 4.6-fold increase in functional antibody titers.

Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination

- Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine - Filing for World Health Organization Emergency Use Listing expected in August 2021 GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt.

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine

Finally, some good news for this emerging biotech.

Why Novavax Is Rallying Again Today

GT Biopharma Inc

Pacific Biosciences of California

Cassava Sciences Inc

Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?

Are Penny Stocks Worth It? 5 That Deserve Your Attention Now

Novavax, Inc. (NASDAQ:NVAX) shares are trading higher by 8.4% at $242.67 on continued strength after the company on Wednesday announced an agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine. Novavax shares are trading higher by 32.5% over the past five sessions amid ongoing COVID-19 delta variant concerns, which have lifted vaccine stocks.

Why Novavax Shares Are Trading Higher Today

New York Times

Alibaba

GATX

Vici Properties

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified The New York Times Company among others.

The New York Times Company Among Today's Trending Stocks

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by over 3% pre-market. This is why it happened.

NVAX Stock Price Increases Over 3% Pre-Market: Why It Happened

Investors could soon have 200 million reasons to celebrate.

Here's Why Novavax Stock Soared Today

NVAX stock is soaring today as the company announces its intention to supply the European Union with much-needed coronavirus vaccines. The post NVAX Stock: The Huge Covid-19 News Helping Novavax Shoot Higher appeared first on InvestorPlace.

NVAX Stock: The Huge Covid-19 News Helping Novavax Shoot Higher

EU member states may buy up to 200 million doses of Novavax's vaccine through 2023.

Novavax surges 23% after scoring COVID-vaccine supply deal with the EU

Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Wednesday after the company announced it finalized an advanced purchase agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine. Novavax was up 20.50% at $227.73 at last check Wednesday.

News for Novavax Stock (NVAX)